TARS — Tarsus Pharmaceuticals, Inc. Stock Price, Chart & AI Report

Positive Oct 28, 2025 • 21:00 UTC GlobeNewswire Inc. • Tarsus Pharmaceuticals, Inc.

Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Tarsus Pharmaceuticals will host a live webcast on November 4, 2025, to report its third quarter 2025 financial results and provide a corporate update. The company has FDA-approved XDEMVY for Demodex blepharitis and is developing additional treatments for eye care and infectious disease prevention.

TARS pharmaceutical webcast financial results eye care XDEMVY Demodex blepharitis

Sentiment note

Company is reporting record quarterly net product sales, expanding its product pipeline, and hosting an investor update, indicating growth and strategic development

Neutral Oct 27, 2025 • 15:15 UTC The Motley Fool • Cory Renauer

Capricorn Fund Loads Up on Phreesia (PHR) With a 484,000 Share Purchase

Capricorn Fund Managers Ltd acquired 484,500 shares of Phreesia, valued at $11.4 million, representing 3.8% of their reportable assets under management. The investment comes as Phreesia reaches a milestone of first quarterly net income and plans to expand payment solutions.

PHR WAY TARS MSFT healthcare SaaS investment patient intake

Sentiment note

Mentioned as a portfolio holding with no specific performance details

Positive Oct 1, 2025 • 17:00 UTC GlobeNewswire Inc. • Delveinsight

Lyme Disease Market Growth Highlighted by Pipeline Advances and Expanding Patient Population | DelveInsight

DelveInsight's analysis predicts growth in the Lyme disease market from 2025-2034, driven by emerging therapies and increased healthcare spending, with new vaccine and prevention technologies in development.

VALN PFE TARS MRNA Lyme disease vaccine healthcare market growth

Sentiment note

Developing TP-05, a novel oral preventive therapy targeting tick vectors

Positive Aug 27, 2025 • 21:00 UTC GlobeNewswire Inc. • Tarsus Pharmaceuticals, Inc.

Tarsus to Participate in Upcoming Investor Conferences

Tarsus Pharmaceuticals plans to participate in two upcoming healthcare investment conferences in September 2025, showcasing its eye care and infectious disease prevention pipeline, including its FDA-approved XDEMVY® treatment for Demodex blepharitis.

TARS WFC WFCPA WFCPC pharmaceuticals eye care investor conferences XDEMVY

Sentiment note

Company is showcasing strong financial performance with 152% year-over-year net product sales increase and expanding its therapeutic pipeline across multiple disease areas

Neutral Aug 27, 2025 • 08:26 UTC Investing.com • Nathan Reiff

3 Biotech Catalysts Present Major Opportunity

Three biotech companies - Boston Scientific, Arcutis Biotherapeutics, and Tarsus Pharmaceuticals - show promising developments in medical devices and drug treatments, with potential for significant investor returns.

BSX ARQT TARS biotech medical devices drug development clinical trials FDA approval

Sentiment note

Wider-than-expected quarterly losses, but strong net sales from XDEMVY treatment, promising Phase II study for ocular rosacea, and 6 out of 7 analysts rating it a Buy with over 16% upside potential

Neutral Jul 30, 2025 • 21:00 UTC GlobeNewswire Inc. • Tarsus Pharmaceuticals, Inc.

Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

Tarsus Pharmaceuticals will host a live webcast on August 6, 2025, to report its second quarter 2025 financial results and provide a corporate update, discussing its eye care and infectious disease prevention pipeline.

TARS webcast financial results eye care pharmaceutical Demodex blepharitis

Sentiment note

Standard corporate financial reporting announcement with no explicit positive or negative indicators, presenting routine investor communication about upcoming quarterly results

Positive May 29, 2025 • 21:00 UTC GlobeNewswire Inc. • N/A

Tarsus to Participate in Upcoming Investor Conferences

Tarsus Pharmaceuticals announced plans to participate in several upcoming investor conferences, including the William Blair 45th Annual Growth Stock Conference, the Jefferies Global Healthcare Conference, and the Goldman Sachs 46th Annual Global Healthcare Conference.

TARS investor conferences Tarsus Pharmaceuticals

Sentiment note

The article announces Tarsus Pharmaceuticals' plans to participate in several upcoming investor conferences, which suggests the company is actively engaging with the investment community and is likely in a strong position to share its business updates and growth prospects.

Neutral May 5, 2025 • 20:40 UTC Benzinga • Vandana Singh

Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal

Elanco Animal Health has sold certain future royalties and commercial milestones associated with its Xdemvy product to Blackstone for $295 million. The company will use the proceeds to reduce its debt and expects to achieve a net leverage ratio of 3.9x-4.3x EBITDA by the end of 2025.

ELAN TARS Elanco Animal Health Blackstone Xdemvy royalties debt reduction

Sentiment note

The article mentions Tarsus Pharmaceuticals as the company that exclusively licensed lotilaner (the active ingredient in Xdemvy) from Elanco, but does not provide any additional information about the company's performance or outlook.

Positive Apr 24, 2025 • 21:00 UTC GlobeNewswire Inc. • N/A

Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

Tarsus Pharmaceuticals, Inc. (TARS) will host a webcast to report its Q1 2025 financial results and provide a corporate update. The company is also presenting data on the global prevalence and patient burden of Demodex blepharitis at the ASCRS 2025 Annual Meeting.

TARS Tarsus Pharmaceuticals financial results corporate update Demodex blepharitis ASCRS 2025 Annual Meeting

Sentiment note

The article highlights Tarsus Pharmaceuticals' upcoming webcast to report financial results and provide a corporate update, as well as its plans to present scientific data at a major industry event. This suggests the company is actively engaged in its business operations and making progress.

Positive Mar 13, 2025 • 01:49 UTC GlobeNewswire Inc. • N/A

Tarsus Announces Pricing of Upsized $125.0 Million Public Offering

Tarsus Pharmaceuticals announced the pricing of an upsized underwritten public offering of 2,808,988 shares of its common stock at a public offering price of $44.50 per share, with the gross proceeds expected to be approximately $125.0 million.

TARS Tarsus Pharmaceuticals public offering common stock

Sentiment note

The company is raising significant capital through a public offering, which suggests confidence in its future prospects and ability to execute on its business plans.

Positive Mar 6, 2025 • 22:00 UTC GlobeNewswire Inc. • N/A

Tarsus to Participate in Upcoming Investor Conference

Tarsus Pharmaceuticals, Inc. announced that it will participate in a fireside chat at the Barclays 27th Annual Global Healthcare Conference on March 11th. The company is advancing its pipeline, including FDA-approved XDEMVY® for the treatment of Demodex blepharitis and TP-04 and TP-05 for the potential treatment of Ocular Rosacea and prevention of Lyme disease, respectively.

TARS Tarsus Pharmaceuticals Barclays Global Healthcare Conference XDEMVY Demodex blepharitis TP-04 Ocular Rosacea TP-05

Sentiment note

The article highlights Tarsus Pharmaceuticals' participation in an industry conference, as well as the advancement of its pipeline, including an FDA-approved product and two potential treatments in development. This suggests the company is actively engaged in its business and making progress.

Positive Feb 20, 2025 • 22:00 UTC GlobeNewswire Inc. • N/A

Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025

Tarsus Pharmaceuticals, Inc. announced that it will host a live webcast to report its fourth quarter and full-year 2024 financial results and provide a corporate update.

TARS Tarsus Pharmaceuticals financial results corporate update

Sentiment note

The article announces that Tarsus Pharmaceuticals will be reporting its financial results and providing a corporate update, which suggests the company is actively engaged in its business operations and providing updates to investors.